Pediatric Clinical Trial Activity for Antipsychotics and the Sharing of Results

Author(s):  
Edel Mc Glanaghy ◽  
Nina Di Pietro ◽  
Benjamin Wilfond
SAGE Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 215824402110163
Author(s):  
Tariq H. Malik ◽  
Chunhui Huo

Result disclosure of clinical trial posts a conflicting logic between private secrecy and public interest. Despite ethical and legal requirements for disclosing clinical trial results, clinical trials’ sponsors tend to withhold the results. We explored the location, timing, and rationale behind the withheld clinical trial results. Based on the entrepreneurial orientation (EO) perspective, we propose that organizational EO contingencies moderate the disclosure decision. We used the completed clinical trial projects in China by foreign and domestic sponsors. First, we found that a unit increase in the sponsor’s experience can increase the disclosure about 1.01 times. Second, we found that industrial enterprises disclose results about 3.7 times more than universities do. Third, we found that foreign clinical trial projects in China tend to disclose 3.9 times more than domestic projects. We link these findings to two types of audience. First, we inform the academic community on the theory and empirics regarding risk-taking behavior in the biopharmaceutical industry’s clinical trial activity. Second, we address the general audiences concerned about the ethical and socioeconomic wellbeing of the public.


2007 ◽  
Vol 35 (11) ◽  
pp. 2615-2623 ◽  
Author(s):  
Ludwik K. Branski ◽  
David N. Herndon ◽  
Clifford Pereira ◽  
Ronald P. Mlcak ◽  
Mario M. Celis ◽  
...  

Author(s):  
Partha Chakraborty

Collaboration is defined as the actions for individuals and teams to work together for a common goal. There are several bottlenecks to an efficient and effective collaborative model of clinical trial including: the lack of a centralized, consistent, globally accessible platform to manage and store essential study related documentation; inconsistent or incomplete work assignments; inefficient notification of key events requiring follow-on action; and incomplete, missing, expired, or redundant documentation and training activities and need to maintain multiple credential to access various system, Removing these barriers is an important part of establishing an environment that fosters collaboration among all constituencies involved in managing clinical trial keeping them connected, informed, and on task by providing access to everyone at any time, from anywhere.The case study below introduces need of an integrated clinical collaboration platform, addressing key functionality of such an platform and describes the architecture & design consideration to industrialize such a platform. The intended audience of this case study is the architects & designers of similar systems. The clinical trial activity for a drug in research is approximately 70% of the overall drug development cost. It is estimated that 4% of the cost of a trial is in 'rework' involving communication, regulatory issues, patient enrollment, document review and replacement of patients. The integrated clinical collaboration platform has potential to eliminate significant amount of cost of re-work, which is in order of $3.5M per trial.


2015 ◽  
Vol 20 (5) ◽  
pp. e73-e73
Author(s):  
WWY Chan ◽  
A Clyburne-Sherin ◽  
P Thurairajah ◽  
M Kapadia ◽  
AW Chan ◽  
...  

2014 ◽  
Vol 17 (7) ◽  
pp. A433
Author(s):  
K. Athanasakis ◽  
N. Boubouchairopoulou ◽  
V. Alexiou ◽  
B. Baroutsou ◽  
J. Kyriopoulos

1994 ◽  
Vol 11 (2) ◽  
pp. 171-172
Author(s):  
G. Hosking ◽  
S. Spencer ◽  
C. Douglas ◽  
A. Yuen

Sign in / Sign up

Export Citation Format

Share Document